Singer Capital Markets is delighted to have been appointed as Corporate Broker to Novacyt S.A. with immediate effect.

About Novacyt Group

Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.

Ticker: NCYT
Market Cap: €32.8 million*
Website: Click here

*As at 12^th September 2025

Account Team

Investment Banking
Tom Salvesen Head of Corporate Broking Email | Call	Phil Davies Managing Director, Investment Banking Email | Call	James Fischer Assistant Director, Investment Banking Email | Call	Samed Ethemi Analyst, Investment Banking Email | Call

Research, Sales, & Trading
Chris Glasper Senior Research Analyst Email | Call	Jonathan Dighe Equity Sales Email | Call	Gareth Henderson Head of Trading Email | Call

Corporate Dealing
Ross Penney Director, Corporate Dealing Email | Call	Fabienne Tuesley Associate, Corporate Dealing Email | Call

Investor Relations
Georgie Cardozo Investor Relations Email | Call